E-Paper
James Murdoch to leave GlaxoSmithKline board
GlaxoSmithKline says that James Murdoch has decided not to seek re-election to the drug company's board.
GlaxoSmithKline says that James Murdoch has decided not to seek re-election to the drug company's board.
GSK said Murdoch wished to focus on his duties as chairman and chief executive of international operations at News Corp. in New York.
James, the son of News Corp chief executive Rupert Murdoch, has been under pressure over his role in the phone hacking scandal at News Corp.'s defunct Sunday tabloid, News of the World. He has said he was unaware of any indication that hacking was rife at the paper, a claim disputed by former colleagues.
Murdoch will leave the GSK board following the annual general meeting on May 3.
Meanwhile, News Corp. announced Matthew Anderson, its London-based director for strategy and corporate affairs in Europe and Asia, was resigning effective March 31 "to return to the San Francisco Bay Area with his family and pursue new opportunities."
Anderson will continue as a senior adviser to the company focusing on select international initiatives and relevant directorships, News Corp. said.
